Correlation
The correlation between TXG and DHR is 0.55, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.
TXG vs. DHR
Compare and contrast key facts about 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: TXG or DHR.
Performance
TXG vs. DHR - Performance Comparison
Loading data...
Key characteristics
TXG:
-0.76
DHR:
-0.81
TXG:
-1.00
DHR:
-1.12
TXG:
0.87
DHR:
0.85
TXG:
-0.60
DHR:
-0.66
TXG:
-1.47
DHR:
-1.42
TXG:
39.43%
DHR:
18.50%
TXG:
76.06%
DHR:
30.34%
TXG:
-96.47%
DHR:
-65.30%
TXG:
-95.29%
DHR:
-34.56%
Fundamentals
TXG:
$1.15B
DHR:
$136.31B
TXG:
-$1.33
DHR:
$5.15
TXG:
1.84
DHR:
5.72
TXG:
1.63
DHR:
2.67
TXG:
$624.66M
DHR:
$23.82B
TXG:
$429.69M
DHR:
$14.23B
TXG:
-$127.01M
DHR:
$7.17B
Returns By Period
In the year-to-date period, TXG achieves a -33.64% return, which is significantly lower than DHR's -17.15% return.
TXG
-33.64%
17.65%
-40.06%
-57.49%
-42.90%
-34.32%
N/A
DHR
-17.15%
-3.46%
-20.56%
-25.70%
-6.30%
5.57%
18.26%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
TXG vs. DHR — Risk-Adjusted Performance Rank
TXG
DHR
TXG vs. DHR - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for 10x Genomics, Inc. (TXG) and Danaher Corporation (DHR). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
TXG vs. DHR - Dividend Comparison
TXG has not paid dividends to shareholders, while DHR's dividend yield for the trailing twelve months is around 0.60%.
| TTM | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
TXG 10x Genomics, Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
DHR Danaher Corporation | 0.60% | 0.47% | 0.43% | 0.38% | 0.26% | 0.32% | 0.44% | 0.62% | 0.60% | 36.46% | 0.80% | 0.47% |
Drawdowns
TXG vs. DHR - Drawdown Comparison
The maximum TXG drawdown since its inception was -96.47%, which is greater than DHR's maximum drawdown of -65.30%. Use the drawdown chart below to compare losses from any high point for TXG and DHR.
Loading data...
Volatility
TXG vs. DHR - Volatility Comparison
10x Genomics, Inc. (TXG) has a higher volatility of 19.84% compared to Danaher Corporation (DHR) at 12.02%. This indicates that TXG's price experiences larger fluctuations and is considered to be riskier than DHR based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
TXG vs. DHR - Financials Comparison
This section allows you to compare key financial metrics between 10x Genomics, Inc. and Danaher Corporation. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
TXG vs. DHR - Profitability Comparison
TXG - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, 10x Genomics, Inc. reported a gross profit of 105.45M and revenue of 154.88M. Therefore, the gross margin over that period was 68.1%.
DHR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2025, Danaher Corporation reported a gross profit of 3.51B and revenue of 5.74B. Therefore, the gross margin over that period was 61.2%.
TXG - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, 10x Genomics, Inc. reported an operating income of -39.33M and revenue of 154.88M, resulting in an operating margin of -25.4%.
DHR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2025, Danaher Corporation reported an operating income of 1.27B and revenue of 5.74B, resulting in an operating margin of 22.2%.
TXG - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, 10x Genomics, Inc. reported a net income of -34.36M and revenue of 154.88M, resulting in a net margin of -22.2%.
DHR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2025, Danaher Corporation reported a net income of 954.00M and revenue of 5.74B, resulting in a net margin of 16.6%.